DeepQure receives IDE Approval from FDA for its EFS Study to Treat Resistant Hypertension

DeepQure receives IDE Approval from FDA for its EFS Study to Treat Resistant Hypertension

By, Admin 11 June 2024

DeepQure receives IDE Approval from FDA for its EFS study to treat Resistant Hypertension with its Extravascular Renal Denervation Technology (HyperQure™)

DeepQure

mDeepQure, a Seoul based medical device company with a novel, extravascular (laparoscopic approach) solution for renal denervation (RDN), today announced initiation of its Early Feasibility Study (EFS) for the HyperQure™ system following FDA IDE approval. HyperQure™ is the world's first extravascular RDN medical device for the treatment of resistant hypertension.

Early Feasibility Study for Safety and Efficacy

  • With this approval, the company will commence the Early Feasibility Study to prove the safety and efficacy of HyperQure™ in 15 patients with resistant hypertension. 
  • The clinical trial will be conducted in a prospective, multicenter, single-arm, open-label design at major U.S. university hospitals, including Stanford University, Mayo Clinic, Emory University, University of Arizona and the University of California, Irvine.

Words from DeepQure Inc.

"We are thrilled that the FDA has approved our IDE study plan. This is a significant US regulatory milestone for DeepQure Inc., starting the feasibility study using the extravascular ablation platform in the US for the Renal Denervation indication. We will accelerate our global clinical trials with this IDE approval,"" says Chang Wook Jeong, co-founder and CMO of DeepQure Inc.

HyperQure

  • HyperQure™ system consists of an energy generator and a laparoscopic instrument that delivers RF energy for ablation directly to the sympathetic nerves around the renal artery by wrapping the renal artery 360 degrees from outside of the vessel. 
  • This mechanism allows full denervation of renal sympathetic nerves without damaging the vascular endothelium which has proven to be a challenge for intravascular (catheter) systems. 
  • The HyperQure system is a simple, straightforward device that is easy to learn and aims to deliver uniform denervation results regardless of the surgeon's skill sets.
  • The Korean First in Human HyperQure™ trial is on-going and initial results are showing strong symptomatic improvements in patients with resistant hypertension – these patients showed uncontrolled hypertension despite taking 5-8 hypertensive drugs. 
  • The RDN treatment utilizing the HyperQure™ system significantly lowered the blood pressure of the patients with no adverse events during and post treatment.

About DeepQure Inc.

  • DeepQure Inc., is a clinical stage medical device company focused on the development of a novel, extravascular (laparoscopic approach) device for the treatment of hypertension.
  • Company is undergoing R&D to expand the technology to treat other cardiovascular diseases such as Atrial Fibrillation.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!